COCP Investor Presentation - 011025 final.pdf

《COCP Investor Presentation - 011025 final.pdf》由会员分享，可在线阅读，更多相关《COCP Investor Presentation - 011025 final.pdf（27页珍藏版）》请在三个皮匠报告上搜索。

1、Investor PresentationJanuary 2025Nasdaq:COCPPotent antivirals to combat some of the most serious diseases facing humanity2Forward-Looking StatementsThis presentation contains forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995,including our developme

2、nt pipeline;our technology platforms ability to produce viable drug candidates at reduced development timelines and costs;development efforts in our clinical programs,including our ongoing Phase 2a study for oral influenza PB2 inhibitor;our ongoing Phase 1 study with 3CL protease inhibitor for coron

3、avirus and norovirus;and the expected sufficiency of our cash balance to fund our planned operations.Forward-looking statements are prefaced by words such as“anticipate,”“expect,”“plan,”“could,”“may,”“will,”“should,”“would,”“intend,”“seem,”“potential,”“appear,”“continue,”“future,”believe,”“estimate,

4、”“forecast,”“project,”and similar words.Forward-looking statements are based on our current expectations and assumptions regarding our business,the economy and other future conditions.Because forward-looking statements relate to the future,they are subject to inherent uncertainties,risks and changes

5、 in circumstances that are difficult to predict.We caution you,therefore,against relying on any of these forward-looking statements.Our actual results may differ materially from those contemplated by the forward-looking statements for a variety of reasons,including,without limitation,the risks arisi

6、ng from any future interest rate increases in response to inflation,uncertainty in the financial markets,the possibility of a recession and the geopolitical conflicts in Israel and Ukraine on our Company,our collaboration partners,and on the U.S.,UK,Australia and global economies,our ability to proc